Inhibition of IDO by administering fludarabine and cyclophosphamide can restore the activity of CD19-specific CAR-T cells against IDO-positive lymphoma in vivo, suggesting that IDO is a potential therapeutic target for enhancing the clinical activity of CAR-T therapy (150, 151) (Figure 1). Here, IDO1 is linked to lymphoma.